Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The pharmaceutical industry, traditionally seen as recession-resistant, may face challenges due to Trump's tariffs and the dominance of GLP-1s. Lexeo is moving forward with a gene therapy for Friedreich's ataxia after promising phase I/II data, while Rallybio is pivoting to a new antibody for rare autoimmune disorders. HHS Secretary Robert F. Kennedy, Jr. will not be speaking to the Senate health committee this week as scheduled. In other news, Merida is entering the autoimmune and allergy arena with a $121 million series A funding. Lilly is suing an Indianapolis spa for selling knockoff versions of its migraine drug Zepbound, and biotech shares are affected by the departure of FDA's Marks. Cardiovascular disease is back in the spotlight.